Last reviewed · How we verify
lurtotecan liposome
At a glance
| Generic name | lurtotecan liposome |
|---|---|
| Sponsor | NCIC Clinical Trials Group |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Lurtotecan Liposome in Treating Patients With Advanced Solid Tumors (PHASE1)
- Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors (PHASE1)
- Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial Cancer (PHASE2)
- Liposomal Lurtotecan in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer (PHASE2)
- Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer (PHASE2)
- Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- lurtotecan liposome CI brief — competitive landscape report
- lurtotecan liposome updates RSS · CI watch RSS
- NCIC Clinical Trials Group portfolio CI